PharmacoEconomics

, Volume 2, Issue 5, pp 355–362 | Cite as

The Australian Guidelines for Subsidisation of Pharmaceuticals

The Road to Cost-Effective Drug Prescribing?
  • Magnus Johannesson
Leading Article

Keywords

Economic Evaluation Indirect Cost Contingent Valuation Pharmaceutical Benefit Scheme Pharmaceutical Benefit Advisory Committee 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Appel LJ, Steinberg EP, Powe NR, Anderson GF, Dwyer SA, et al. Risk reduction from low osmolality contrast media: what do patients think it is worth? Medical Care 28: 324–337, 1990PubMedCrossRefGoogle Scholar
  2. Buchanan JM. Cost and choice: an inquiry in economic theory. Markham Publishing Company, Chicago, 1969Google Scholar
  3. Berger MC, Blomquist GC, Kenkel D, Tolley GS. Valuing changes in health risks: a comparison of alternative measures. Southern Economic Journal 53: 967–984, 1987CrossRefGoogle Scholar
  4. Commonwealth of Australia. Draft guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits committee, including submissions involving economic analyses. Department of Health, Housing and Community Services, Canberra, 1990Google Scholar
  5. Cooper BS, Rice DP. The economic cost of illness revisited. Social Security Bulletin 39: 21–36, 1976PubMedGoogle Scholar
  6. Cummings RG, Brookshire DS, Schulze WD. Valuing environmental goods. Rowman & Allanheld, New Jersey, 1986Google Scholar
  7. Donaldson C. Willingness to pay for publicly provided goods: a possible measure of benefit? Journal of Health Economics 9: 103–118, 1990PubMedCrossRefGoogle Scholar
  8. Drummond MF. Economic evaluation and the rational diffusion and use of health technologies. Health Policy 7: 309–324, 1987PubMedCrossRefGoogle Scholar
  9. Drummond MF. Australian guidelines for cost-effectiveness analysis of pharmaceuticals: the thin end of the boomerang? University of York, Centre for Health Economics. Discussion Paper 88, 1991Google Scholar
  10. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford, 1987Google Scholar
  11. Evans D, Freund D, Dittus R, Robertson J, Henry D. The use of economic analysis as a basis for inclusion of pharmaceutical products on the pharmaceutical benefits scheme. Department of Health, Housing and Community Services, Commonwealth of Australia, Canberra, 1990Google Scholar
  12. Henry D. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1: 54–67, 1992PubMedCrossRefGoogle Scholar
  13. Johannesson M. Buchanan’s opportunity cost concept. the contingent valuation method and cost-benefit analysis. Journal des Economistes et des Etudes Humaines 2: 123–133, 1991Google Scholar
  14. Johannesson M. Economic evaluation of lipid lowering: a feasibility test of the contingent valuation approach. Health Policy 20: 309–320, 1992PubMedCrossRefGoogle Scholar
  15. Johannesson M, Fagerberg B. A health economic comparison of diet and drug treatment in obese men with mild hypertension. Journal of Hypertension, in press, 1992Google Scholar
  16. Johannesson M, Johansson P-O, Jönsson B. Economic Evaluation of drug therapy: a review of the contingent valuation method. PharmacoEconomics 1: 325–337, 1992PubMedCrossRefGoogle Scholar
  17. Johannesson M, Jönsson B. Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy 17: 1–23, 1991aPubMedCrossRefGoogle Scholar
  18. Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment: a review of methodological issues. Health Policy 19: 55–78, 1991bPubMedCrossRefGoogle Scholar
  19. Johannesson M, Jönsson B, Borgquist L. Willingness to pay for antihypertensive therapy: results of a Swedish pilot study. Journal of Health Economics 10: 461–474, 1991aPubMedCrossRefGoogle Scholar
  20. Johannesson M, Åberg H, Agréus L, Borgquist L, Jönsson B. Cost-benefit analysis of non-pharmacological treatment of hypertension. Journal of Internal Medicine 230: 307–312, 1991bPubMedCrossRefGoogle Scholar
  21. Johansson P-O. An introduction to modem welfare economics. Cambridge University Press, Cambridge, 1991CrossRefGoogle Scholar
  22. Loomes G, McKenzie L. The use of QALYs in health care decision making. Social Science and Medicine 28: 299–308, 1989PubMedCrossRefGoogle Scholar
  23. Mehrez A, Gafni A. Quality-adjusted life years, utility theory and healthy-years equivalents. Medical Decision Making 9: 142–149, 1989PubMedCrossRefGoogle Scholar
  24. Mehrez A, Gafni A. The healthy years equivalents: how to measure them using the standard gamble approach. Medical Decision Making 11: 140–146, 1991PubMedCrossRefGoogle Scholar
  25. Mishan EJ. Evaluation of life and limb: a theoretical approach. Journal of Political Economy 79: 687–705, 1971CrossRefGoogle Scholar
  26. Mishan EJ. Cost-benefit analysis, 2nd ed., Praeger, New York. 1976Google Scholar
  27. Mitchell RC, Carson RT. Using surveys to value public goods. Resources for the Future, Washington, D.C., 1989Google Scholar
  28. Russel L. Is prevention beller than cure? Brookings Institution, Washington, D.C., 1986Google Scholar
  29. Schelling TC. The life you save may be your own. In Chase SB (Ed.) Problems in public expenditure analysis. Brookings Institution, Washington, D.C., 1968Google Scholar
  30. Thompson MS. Willingness to pay and accept risks to cure chronic disease. American Journal of Public Health 76: 392–396, 1986PubMedCrossRefGoogle Scholar
  31. Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. Journal of Public Economics 2: 147–157, 1973CrossRefGoogle Scholar
  32. Weinstein MC. Principles of cost-effective resource allocation in health care organisations. International Journal of Technology Assessment in Health Care 6: 93–103, 1990PubMedCrossRefGoogle Scholar
  33. Weisbrod B. Economics of public health. University of Pennsylvania Press, 1961Google Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Magnus Johannesson
    • 1
    • 2
  1. 1.Centre for Health EconomicsStockholm School of EconomicsStockholmSweden
  2. 2.Department of Health Policy and ManagementHarvard School of Public HealthBostonUSA

Personalised recommendations